Skip to main content

Seborrheic Dermatitis News

FDA Medwatch Alert: Do Not Purchase or Use Skin-Cap Aerosol Spray Products Because They May Be Harmful to Your Health

October 30, 2024 – FDA is warning consumers to not purchase or use Skin-Cap aerosol spray products because they may contain undisclosed steroids. This product, sold by Chemigroup France, formerly...

FDA Approves Arcutis’ Zoryve (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

Zoryve foam represents a highly effective, safe, well-tolerated, once-daily steroid-free foam for use on all affected areas of the body, including hair-bearing areas, with no limitations on duration...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Dermatological Disorders

Related drug support groups

prednisone, clobetasol, dexamethasone, Therapeutic